Tomoe Abe, Yasutaka Takeda, Ichiro Sakuma, Mizuho Okada, Ayaka Kurigaki, Ryoichi Bessho, Mao Sato, Hiroya Kitsunai, Yumi Takiyama, Masaru Sakurai: Efficacy of alogliptin/metformin fixed-dose combination tablets and vildagliptin/metformin fixed-dose combination tablets on glycemic control in real-world clinical practice for the patients with type 2 diabetes: a multicenter, open-label, randomized, parallel group, comparative trial. Metabolic syndrome and related disorders 22:651-660, 2024.
Serina Kita, Hiroshi Okuyama, Takaya Kondo, Mizuki Hayashi, Shinichiro Nakao, Toshitaka Sawamura, Keiji Fujimoto, Atsushi Nakagawa, Hitoshi Yokoyama, Kengo Furuichi: Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using Roxadustat. Clinical case reports 2024 Sep 3;12(9):e9400, 2024.
2023年度
Kota Takuma#, Ayako Fuchigami#, Fumika Shigiyama, Naoki Kumashiro(Corresponding), Takahisa Hirose(Corresponding): Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: a sub-analysis of the DIVERSITY-CVR study. Diabetes, Obesity and metabolism, 25:2131-2141, 2023 (#: Contributed equally)
Daisuke Koya, Stefan D Anker, Luis M Ruilope, Peter Rossing, ZhiHong Liu, Byung Wan Lee, Chien-Te Lee, Charlie Scott, Peter Kolkhof, Robert Lawatscheck, Lili Wang, Amer Joseph, Bertram Pitt(Corresponding); FIDELIO-DKD Investigators: Cardiorenal outcomes with finerenone in Asian patients with chronic kidney disease and type 2 diabetes: a FIDELIO-DKD post hoc analysis. American Journal of Nephrology, 54:370-378, 2023
2022年度
Hiruma S, Shigiyama F, Kumashiro N (Corresponding): Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with nonalcoholic fatty liver disease: A prospective randomized study. Diabetes Obes Metab 25:1576-1588, 2023
Hidaka N, Koga M, Kimura S, Hoshino Y, Kato H, Kinoshita Y, Makita N, Nangaku M, Horiguchi K, Furukawa Y, Ohnaka K, Inagaki K, Nakagawa A, Suzuki A, Takeuchi Y, Fukumoto S, Nakatani F, Ito N(Corresponding): Clinical challenges in diagnosis, tumor localization and treatment of tumor-induced osteomalacia: outcome of a retrospective surveillance. Journal of Bone and Mineral Research, 37: 1479-1488, 2022
Shimada K, Kanasaki K, Kato M, Ogura Y, Takagaki Y, Monno I, Hirai T, Kitada M, Koya D(Corresponding): Adenosine/adenosine type 1 receptor signaling pathway did not play dominant roles on the influence of sodium-glucose cotransporter 2 inhibitor in the kidney of bovine serum albumin-overloaded streptozotocin-induced diabetic mice. Journal of Diabetes Investigation, 13: 955-964, 2022
Xu J, Hirai T, Koya D, Kitada M (Corresponding): Effects of SGLT2 inhibitors on atherosclerosis: lessons from cardiovascular clinical outcomes in type 2 diabetic patients and basic researches. Journal of Clinical Medicine, 11: 137, 2022
Miyamoto S(Corresponding), Heerspink HJL, Zeeuw D, Toyoda M, Suzuki D, Hatanaka T, Nakamura T, Kamei S, Murao S, Hida K, Ando S, Akai H, Takahashi Y, Koya D, Kitada M, Sugano H, Nunoue T, Nakamura A, Sasaki M, Nakatou T, Fujimoto K, Kawanami D, Wada T, Miyatake N, Yoshida M, Shikata K, the CANPIONE study Investigators: Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study. Diabetes, Obesity and Metabolism 24:1429-1438, 2022